After finishing his education, Anders Götzsche joined PwC in 1991. From 1998 he was a Sales Manager with the SAS Institute until 2001, after which he became Director of Group Accounting and Reporting in Group 4 Falck. From 2005 Anders held the post of Chief Financial Officer for the Berlingske Officin. He joined Lundbeck in 2007 as Chief Financial Officer, and in November 2017 he was appointed Interim Chief Executive Officer.
Anders holds a Master of Science in Accounting from University of Southern Denmark (1991), and he became a state-authorized public accountant in 1997.
Anders is the Chairman in Rosborg Møbler A/S and serves on the Board of Directors of Veloxis Pharmaceutical A/S.
Following his degree in medicine and research fellow positions at Copenhagen hospitals, Anders Gersel Pedersen worked for Eli Lilly for 11 years: 10 of these as a director overseeing worldwide clinical research in oncology. In 2000 he joined Lundbeck as Vice President of International Clinical Research, he was later appointed Executive Vice President of Drug Development and in 2011 appointed responsible for all Research & Development activities at Lundbeck.
Anders is a member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology, the Danish Society of Medical Oncology and the Danish Society of Internal Medicine. He also serves on the Board of Directors at Bavarian Nordic A/S and ALK-Abelló A/S and is Deputy Chairman in Genmab A/S.
Jacob Tolstrup began his career with Abbott Laboratories in 1997. In 1999, he joined Lundbeck and has since been working in several positions including Finance, Investor Relations and Corporate Communication and has worked in Lundbeck’s affiliate in the US for approximately four years.
Before taking on the role as Executive Vice President, Commercial Operations, Jacob was head of Corporate Functions which comprised of Corporate Business Development, Corporate Human Resources, Investor Relations and Corporate Communication & Public Affairs.
Jacob holds a Master of Science in Business Administration & Commercial Law from Aalborg University, Denmark and an MBA from European Business College, Munich, Germany.
Having completed his degree, Lars Bang began his career at Lundbeck in 1988 as a trainee in R&D. He has later been heading R&D Planning, Corporate Planning and Strategy, Lundbeck España S.A, Group Sales & Marketing. In 2003 he was appointed Group Senior Vice President Supply Operations & Engineering.
Lars holds a Master of Science degree in Engineering from the Technical University of Denmark and a Bachelor of Commerce degree in Marketing from the Copenhagen Business School.
Lars is a member of the Board of Fertin Pharma A/S.
Peter Anastasiou began his career in the pharmaceutical industry at Eli Lilly in 1992, where he stayed for more than 11 years. He then moved on to senior positions in Bristol-Myers Squibb and Neuronetics, Inc. before joining Lundbeck in 2009. Peter has held several positions within Lundbeck’s psychiatry and neurology franchises. Since 2016, he has been President of Lundbeck North America overseeing the operations of both the U.S. and Canadian businesses.
Peter holds a bachelor in economics and management from Albion College and an MBA in general management from Indiana University – Kelly School of business.
Peter is a member of the board of Bear Necessities Pediatric Cancer Foundation and PhRMA (Pharmaceutical Research and Manufacturers of America).
*Peter Anastasiou participates in the Executive Management in his role as Executive Vice President for North America, but he is not a member of the Executive Management as registered with the Danish Business Authority.